Roquette 2025 Full-Year Results Announcement

Roquette’s 2025 results show the resilience of its expanded portfolio in a very difficult market environment.

The Group’s strategy and recent acquisitions enable upselling to higher-value markets.

• +8% turnover growth to €4.9 billion (-5% Like-For-Like basis, LFL^[1]) and +13% Current EBITDA increase to €612 million, driven by the pharmaceutical and food specialties businesses.
• +54 bps increase in Current EBITDA margin to 12.6% showing the value of recent strategic acquisitions and the resulting evolution of the Group’s portfolio.
• Excluding the cash impact of the IFF Pharma Solutions acquisition, Free Cash-Flow landed at €301 million.
• In 2025, Roquette maintained a robust balance sheet with a strong liquidity position and a net debt to combined Current EBITDA ratio of 3.48x versus 3.72x end of June.
• Early 2026, Roquette launched ‘Shift & Lead’, a comprehensive company plan to reinforce its competitiveness, strengthen its market position, and provide long-term value creation to all stakeholders.

Lille – March 19^th, 2026 – Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, today announced its 2025 full-year results, following the approval of its financial statements by the Board of Directors.

Thierry Fournier, CEO of Roquette, commented on the period: “We are seeing the significant benefits of our recent strategic moves and acquisitions, which allow Roquette to offer a more comprehensive portfolio and reinforce our focus on high-value products and markets. Despite a very challenging environment characterized by soft demand, overcapacity, and persistent geopolitical and economic uncertainties, our specialty products remain the key driver of our resilient performance in 2025.”

Regarding the Health & Pharma Solutions Business Unit, the strong performance from new product lines coming from the recent IFF Pharma Solutions acquisition mitigated the effect of softer demand and destocking in the starch and capsules markets, with notable gains from cellulose and alginates products for oral dosage. 

The Nutrition & Bioindustry Business Unit delivered strong results in food specialties, even in the face of sluggish markets and intense competition, with higher demand in food and nutrition, particularly for fiber and protein products. Combined with increased unit prices and lower variable costs, this has resulted in significant margin improvements for specialty products.

Collectively, these achievements strengthened Roquette’s market position and delivered resilient results in a complex landscape, affirming how the company’s strong foundations allow it to continue growing in a volatile and highly competitive environment. “Throughout 2026, we will maintain our commitment to operational excellence, innovation, financial discipline, and cash generation. Guided by our purpose: “Together, we turn the potential of nature into the essentials of life”, we are determined to become the global leader in sustainable plant-based solutions, driven by outstanding innovation and strong client partnerships that shape the future of nutrition, health and bioindustry. By defining and executing ‘Shift & Lead’, our comprehensive company plan, we will reinforce our competitiveness, strengthen our market position, and build for long-term value creation for all our stakeholders”, concluded Thierry Fournier. 

[1] Like-For-Like basis excludes exchange rates impact and perimeter variation.

Download below the full press release.